At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
RO7049389 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Fixed Sequence, Two-Period Study to Investigate the Effect of RO7049389 on the Pharmacokinetics of Pitavastatin in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating RO7049389 and Pitavastatin for Healthy Volunteers. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The main purpose of the study is to characterize the interaction between RO7049389 and the cholesterol-lowering drug, pitavastatin, in healthy volunteers. There is no intended clinical benefit to this study. The total duration of the study for each participant is approximately 12 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartNov 2018
Primary CompletionDec 2018
TodayJul 2026
First PostedOct 24, 2018
Enrollment StartNov 7, 2018
Primary CompletionDec 17, 2018
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 7.7 years ago
Interventions
RO7049389drug
RO7049389 will be taken orally, in tablet form, BID on Days 1-6 of Period 2.
Pitavastatindrug
Pitavastatin will be taken orally, in tablet form, once on Day 1 of Period 1, and once on Day 4 of Period 2.